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The objective of this multicenter retrospective study was to describe clinical presentation, treatment, 25 
outcome, and determine prognostic factors for dogs with presumed primary colorectal lymphoma 26 
(PCRL). Thirty-one dogs were included. The predominant features of PCRL were high grade (n=18) 27 
and immunophenotype B (n=24). Most dogs were substage b (n=25) with higher prevalence of 28 
haematochezia (n=20). One dog had surgery only. Thirtydogs received chemotherapy; amongst them 29 
13  had surgery or radiotherapy.  Progression free survival (PFS) was 1318 days and disease-related 30 
median survival time (MST) 1845 days. Fourteen dogs were alive at the end of the study with a 31 
median follow-up time of 684 days (3- 4678 days). Younger dogs had longer PFS (p=0.031) and 32 
disease-related MST (p=0,01).Presence of haematochezia corresponded with longer PFS (p=0.02). 33 
Addition of local treatment to chemotherapy did not significantly improve the outcome (p=0.584). 34 
Canine PCRL has considerably longer PFS and MST than other forms of non-Hodgkin’s lymphoma.  35 
Keyword: canine, lymphoma, chemotherapy, colorectal 36 
Abbreviations 37 
AL: Alimentary Lymphoma 38 
CI: Confidence Interval 39 
CR: Complete Response 40 
GI: Gastrointestinal 41 
MST: Median Survival Time 42 
PCRL: Primary Colorectal Lymphoma  43 
PFS: Progression Free Survival 44 
PR: Partial Response 45 
Introduction 46 
Canine gastrointestinal (GI) lymphoma, also named alimentary lymphoma (AL), is second in 47 
frequency to the multicentric form and accounts for 5-7% of all canine lymphomas.1 In human 48 
medicine, AL is defined according to Dawson’s criteria2 (Figure 1), in which the lymphoma is 49 
considered alimentary only if the predominant lesion lies within the GI tract, with lymph node 50 
involvement confined to the lymph node chain draining that specific GI segment. In veterinary 51 
medicine, this definition historically has been extended and AL in general is described as the primary 52 
infiltration of neoplastic lymphocytes in the GI tract with or without additional extra-GI involvement 53 
confined to the abdominal cavity.3 Most of the dogs affected by AL present late in the course of the 54 
disease with severe GI clinical signs and have rapid progression with a worse outcome than the 55 
multicentric form4: median survival time for canine AL ranges from 0.5 to 2.5 months,4,5 versus 10 to 56 
12 months for the multicentric form.1 This difference in prognosis can be attributed to the negative 57 
prognostic factors carried by the most common presentation of canine GI lymphoma: T-cell 58 
immunophenotype, high grade and substage b.4,5,6,7 However dogs with AL typically do worse than 59 
dogs with multicentric lymphoma carrying similar negative prognostic factors so it is unknown if  60 
there are additional inherent features of AL, such as specific morphologic subtype  that could account 61 
for its poorer prognosis. Chemotherapy and supportive care are the standard of treatment for AL in 62 
dogs. A specific chemotherapy protocol (VELCAP-SC: vincristine, L-asparaginase, 63 
cyclophosphamide, doxorubicin, prednisolone - short, consolidated) for canine AL resulted in an 64 
overall median survival time of 77 days for the whole population and of 117 days for the 65 
chemotherapy responders.4   66 
Primary large intestinal lymphoma can arise primarily from the colon, the rectum or both. In human 67 
medicine, it is referred to as primary colorectal lymphoma (PCRL) regardless of the segment of large 68 
intestine it is originating from. Canine PCRL is a rare presentation of AL, which has been sparsely 69 
described in the veterinary literature within case series reporting information about response and 70 
outcome for all GI locations.3-6,8 When specific information for dogs with large intestinal lymphoma 71 
has been reported in those studies, a better outcome than other GI locations has been observed3-5,8,9 72 
with remission times up to 54 months (Table 1). A recent case series of 11 dogs with rectal lymphoma 73 
treated with surgery (7/11) and/or chemotherapy (8/11) described a mean survival time of 1697 days, 74 
with a median not reached10. This data suggests that PCRL could have a better prognosis than AL in 75 
other locations. Such difference in prognosis could have implications in veterinary practice as some 76 
owners or veterinarians might be reluctant to treat dogs diagnosed with PCRL due to the currently 77 
described overall poor prognosis for AL. Questions that remain unanswered at the moment are: if 78 
studies with a higher number of patients would corroborate a distinct prognosis and a specific clinical 79 
presentation for canine PCRL; which prognostic factors are associated with this presentation and 80 
which therapeutic approach would have the best outcome. The purpose of the present multi-center 81 
retrospective study is to provide further information to answer those questions.  82 
 83 
Material and methods 84 
Case selection:  85 
Dogs were presumed to have PCRL if they had absence of peripheral lymphadenopathy, a cytologic 86 
or histologic diagnosis of lymphoma had been made based on examination of a mass or diffuse 87 
intestinal wall infiltration of rectum, colon, or both and the main clinical signs at presentation were 88 
associated to large intestinal involvement. Dogs with concurrent abdominal lymphadenopathy, 89 
hepatomegaly and splenomegaly were eligible for inclusion. Exclusion criteria included presence of 90 
gross disease in other areas of the GI tract evidenced by abdominal imaging or direct visualization at 91 
surgery. 92 
The American College of Veterinary Internal Medicine Oncology Diplomate list serve was used to 93 
recruit cases for this retrospective study for which a diagnosis of PCRL was established. Medical 94 
records of dogs diagnosed with PCRL between 2000 and 2013 at the Queen Mother Hospital for 95 
Animals, Royal Veterinary College, London, United Kingdom; The College of Veterinary Medicine, 96 
Washington State University, Pullman, Washington State, USA; East Bay Veterinary Specialists, 97 
Walnut Creek, California, USA; Animal Cancer Center, Colorado State University, Fort Collins, 98 
Colorado, USA; The Hope Center for advanced Veterinary Medicine, Vienna, Virginia, USA; The 99 
Veterinary Cancer Center, Norwalk, Connecticut, USA; School of Veterinary Medicine, Purdue 100 
University, West Lafayette, Indiana, USA; Chavat Daat Veterinary Speciality Center, Beit Berl, 101 
Israel; Veterinary Medical Center, Michigan State University, East Lansing, Michigan, USA; 102 
Mississauga Oakville Veterinary Emergency Hospital and Referral Services, Oakville, Ontario, 103 
Canada; School of Veterinary Medicine, University of Madison-Wisconsin, Wisconsin, USA; 104 
Veterinary Specialty Center at Veterinary Emergency Service, Middleton, Wisconsin, USA; 105 
Southwest Veterinary Oncology, Gilbert, Arizona, USA; Alta Vista Animal Hospital , Ottawa, 106 
Ontario, Canada;  Veterinary Medical Center, Ohio State University, Columbus, Ohio, USA; Animal 107 
Specialty and Emergency Center (ASEC), Los Angeles, California, USA; Vets Now Referrals, Blue 108 
Bell Hill, Kent, UK; were retrospectively reviewed.  109 
Medical records review: 110 
Data abstracted from the medical record included signalment, date and weight at diagnosis, presenting 111 
clinical signs, duration of the clinical signs, prior treatment(s), location of disease, method of 112 
diagnosis (cytology or histopathology), lymphoma grade and immunophenotype, results of clinical 113 
staging performed including physical examination findings, imaging technique used (thoracic 114 
radiographs, abdominal ultrasound, colonoscopy or CT scan) and bone marrow aspirate results, 115 
laboratory test results (including complete blood count, serum biochemical profile, urinalysis and 116 
faecal analysis when available), treatment modality (surgery, radiation therapy protocol, 117 
chemotherapy protocol(s)), response to therapy, date and cause of death or last follow-up visit. 118 
Necropsy results were recorded when available. Results of clinicopathological testing were classified 119 
as normal or abnormal by comparison with established reference ranges for the participating 120 
institution where the test was performed.  121 
Histological reevaluation was performed for all cases for which samples were available. Lymphoma 122 
grading was performed with grading system employed at the discretion of the pathologist reviewing 123 
the slides for cases with histopathology and according to cell size for those with cytological 124 
diagnosis.11-13 Immunohistochemistry or immunocytochemistry was performed using antibodies 125 
against CD3 and CD79 for all cases for which samples were available and in which 126 
immunophenotyping had not been performed. Immunophenotyping was also performed with PCR for 127 
antigen receptor re-arrangement (PARR) in some cases. 128 
Dogs were clinically staged at diagnosis according to the World Health Organization (WHO) criteria 129 
for canine lymphoma.1 Dogs were further classified as substage a (having no clinical signs) or 130 
substage b (having systemic signs or clinical signs associated to the gastrointestinal presentation of 131 
lymphoma with potential impact on systemic status, as previously described for assessment of 132 
substage in canine AL). Clinical signs included in the b substage category were haematochezia, 133 
tenesmus, diarrhoea, vomiting, lethargy, or decreased appetite. Haematochezia, tenesmus, vomiting, 134 
and diarrhoea were considered local clinical signs; lethargy and decreased appetite were considered 135 
systemic signs. Information regarding exact anatomic location and extent of the disease was gathered 136 
from the physical examination and staging test results.  137 
Therapeutic modality was recorded for each patient. When surgery was performed, information 138 
regarding the type and extent of surgery (i.e. excisional or incisional biopsy, date of procedure, and 139 
regional lymph node(s) removal) was recorded. Only dogs that had an excisional surgery were 140 
considered to have had surgery as a treatment. Surgical technique was recorded when available.  For 141 
patients that were treated with radiation therapy, type and protocol (dose, number and frequency of 142 
fractions) were recorded. For chemotherapeutic treatments, information regarding protocols 143 
(induction and rescue) including drug, dose, administration frequency and protocol duration, was 144 
recorded. For descriptive purposes, the first chemotherapy protocol used was categorised as: CHOP 145 
type protocol, doxorubicin single agent, COP type protocol, lomustine-based protocol, prednisolone 146 
and chlorambucil or prednisolone alone. CHOP protocols could be of different length (19 or 25 147 
weeks) and sometimes included L-asparaginase, or epirubicin instead of doxorubicin; the COP type 148 
protocols sometimes included a dose of cytarabine (COAP protocol).  149 
Response to treatment was classified according to remission status recorded by the veterinarian 150 
providing the data using the following categories: complete response (CR), partial response (PR), 151 
stable disease, and progressive disease. Response to treatment was mainly determined based on results 152 
of clinical examination and assessment of progression of clinical signs. When available, follow-up 153 
abdominal ultrasound examinations were used to assess for changes in internal organs. Complete 154 
response was defined as resolution of all clinical signs and disappearance of all clinical evidence of 155 
disease on the basis of physical examination (via rectal and abdominal palpation) or follow-up 156 
abdominal ultrasound examination. Partial response was defined as (≥) 50 and (<) 100% reduction in 157 
size of measurable disease on the basis of physical examination (via rectal and abdominal palpation) 158 
or follow-up abdominal ultrasound examination associated or not with improvement of the clinical 159 
signs. No response was defined as no changes or deterioration in clinical signs, and less than 50% 160 
reduction, increase in the size of measurable disease or appearance of new lesions on the basis of 161 
physical examination (via rectal and abdominal palpation) or follow-up abdominal ultrasound 162 
examination.14 When surgery was performed prior to chemotherapy, only dogs with residual 163 
macroscopic disease were included in the assessment of response to chemotherapy.  164 
Statistical analysis: 165 
Categorical data are presented either as percentages or ratios. Continuous data are presented as 166 
median (range). Survival time was defined as the time from diagnosis until natural death or 167 
euthanasia. Deaths due to disease progression were considered events for the disease-related median 168 
survival time. Dogs that were lost to follow-up, still alive at the end of the study period or died from 169 
causes unrelated to the lymphoma were censored. In addition, overall survival time was also 170 
calculated. Due to the small number of patients that died from lymphoma, this variable included all 171 
deaths as events (related to lymphoma or unrelated) with dogs lost to follow-up or still alive at the end 172 
of the study period being censored. Progression free survival was defined as the time from initiation 173 
of treatment to event. For this variable the date of relapse was considered as the endpoint for dogs 174 
when this occurred. Dogs that had not relapsed during the study period were censored at the last date 175 
they were contacted or evaluated by the vet or the date of death free of disease.  176 
After statistical description of the patient population, survival analysis using Kaplan-Meier product 177 
limit method was conducted to estimate disease-related median survival time (MST), median overall 178 
survival time, and progression free survival (PFS), for the whole population of PCRL patients. 179 
Disease-related MST and PFS of dogs distributed in groups on the basis of various potential risk 180 
factors (univariate analysis) was also calculated. Exploratory statistical analysis for each categorical 181 
risk factors (age, location of the disease, involvement of organs other than the large intestine, 182 
substage, number of clinical signs present, type of clinical signs (local vs systemic), grade, 183 
immunophenotype, treatment type, chemotherapy protocol) used the logrank test to compare 184 
estimated PFS and disease-related MST between categories. Multivariate analysis was not performed 185 
due to the small number of animals in each group and high censorship of dogs in the study. A value of 186 
p ≤ 0.05 was considered significant. All calculations were performed with the aid of a standard 187 
statistical softwarea.  188 
Results 189 
Signalment: Thirty-one dogs met the inclusion criteria for this study and consisted of 17 spayed 190 
females and 14 males (12 neutered and 2 intact). The median age at diagnosis was 5 years (range 1.5-191 
13.5 years old). Median weight was 23.8 kg (range 5.9-52.1 kg). The most common breeds were cross 192 
breeds (7 dogs; 22.6%), and Labrador retrievers (4 dogs; 12.9%). 193 
Clinical signs at diagnosis: Presenting clinical signs were known for 29 of 31 dogs. Twenty-five 194 
(80.64%) dogs had clinical signs at presentation associated with the disease and were considered 195 
subtage b. Haematochezia was the most common presenting clinical sign (n = 20; 64.5%) with 13 of 196 
these dogs presenting additional clinical signs. Other reported clinical signs included: tenesmus in 197 
35.6 % (n=11), diarrhea in 25.8 % (n=8), narrow diameter of faeces in 12.9% (n=4), vomiting in 3.4% 198 
(n=1), lethargy in 3.4% (n=1). Eighteen dogs (58%) had simultaneously 2 to 4 different clinical signs 199 
and 7 dogs (22.5%) had one clinical sign at presentation. Presence of a rectal mass was described on 200 
physical examination in 35.6 % (n=11) and rectal prolapse in 9.68% (n=3). The median duration of 201 
clinical signs was 21 days (range 1-120 days) for the 28 dogs for which this information was 202 
available.  203 
Staging and location of the disease: As per inclusion criteria, none of the dogs had peripheral 204 
lymphadenopathy identified on physical examination. Imaging was performed in 29 patients: 2 dogs 205 
had imaging of thorax and abdomen as well as bone marrow evaluation, 19 had imaging of the thorax 206 
and abdomen, 7 dogs had only abdominal imaging and 1 had only thoracic imaging. Abdominal 207 
imaging consisted of ultrasonography in 24 dogs, radiographs in 2 and computed tomography in 2. 208 
Thoracic imaging was performed in 2 dogs with CT scan and in 20 with radiographs. Dogs that did 209 
not have abdominal imaging had direct evaluation of the GI tract via laparotomy or endoscopy. 210 
A solitary mass was found in 23 patients (17 rectal masses of which 4 dogs also had regional lymph 211 
node involvement, 6 colonic masses of which 5 dogs also had regional lymph node involvement). 212 
Multiple masses were identified in 5 patients, with 1 dog having multiple masses in the rectum, 1 dog 213 
with multiple masses in the colon, and 3 dogs having masses occurring in both areas. Three dogs were 214 
determined to have lymphoma diffusely throughout the colorectal region. Regional lymphadenopathy 215 
was present in 12 dogs with lymphoma confirmed by lymph node cytology for 8 dogs. Splenic 216 
aspirates were performed in 2 dogs and liver aspirates in 4 dogs. Liver involvement was confirmed in 217 
1 dog based on cytology. 218 
Immunophenotype and grade: Three cases were diagnosed via cytology and 28 by histopathology. 219 
Histological or cytological assessment of lymphoma grade was reported for 29 cases (94%) and 2 220 
cases were reported to be low grade lymphoma, 9 were intermediate grade lymphoma, and 18 high 221 
grade lymphoma (Table 2). Slides of 22 cases were obtained for review by a pathologist (7 different 222 
pathologists reviewed all the slides with 2 of them reviewing a total of 16 slides- KS and BP), in those 223 
confirmation of diagnosis and grade was performed. None of the cases which had a grade previously 224 
done and for which histopathology slides were reviewed had a change in their grade. 225 
Immunophenotype was available for 26 patients (84%). It was performed via immunohistochemistry 226 
for 23 dogs and this took place at the time of pathology review for 12 cases. Immunophenotype was 227 
determined by immunocytochemistry for 2 dogs and PARR for 1 dog. There were 24 B-cell 228 
lymphomas, 1 T-cell lymphoma and 1 non-B non-T cell lymphoma. (Table 2).  229 
Treatment and response to treatment: All dogs received therapy, and all but one (that had only 230 
surgery) received chemotherapy as part of the treatment plan. Seventeen patients (55.5%) received 231 
chemotherapy as a sole treatment and thirteen (42%) received chemotherapy in addition to local 232 
treatment. Nine dogs (29%) had surgery prior to adjuvant chemotherapy. Four dogs (13%) had 233 
chemotherapy combined with radiation therapy. These cases received radiation therapy with photons; 234 
protocols comprised hypofractionated regimens for 3 dogs (2 dogs received 2 fractions of 6 Gy and 235 
one dog received one fraction of 6 Gy) and the fourth dog was treated with a hyperfractionated 236 
protocol (19 fractions of 1.5 Gy). One dog (2.5%) had surgery alone. 237 
Out of the ten patients that had surgery, nine dogs (29%) presented with a solitary mass. The 238 
remaining dog had a solitary mass removed from the rectum and was found to have diffuse disease in 239 
the colon at later staging. Two dogs also had lymph node involvement and one of them had the lymph 240 
nodes biopsied at the same surgery. Eight dogs (25.8%) had surgery performed by the referring vet 241 
prior to referral and there was no evidence of previous diagnosis based on cytology or biopsy for the 242 
two remaining dogs so it is likely that surgery in the 10 patients was performed as a mean to obtain a 243 
diagnosis as well as therapeutic procedure. Due to the retrospective nature of the study, the primary 244 
intent of performing surgery could not be ascertained. Type of surgery was recorded for 2 patients: 245 
one had mucosal resection and one had end-to-end anastomosis. The latter procedure was performed 246 
because the dog was initially referred for a rectal polyp previously diagnosed on endoscopic biopsies 247 
performed by the referring vet and lymphoma was diagnosed on the surgical histopathology. Eight 248 
patients out of the 28 diagnosed via histopathology (25.8%) had endoscopic biopsies.  249 
The distribution of induction chemotherapy protocols used was as follows: 18 (58.1%)  patients 250 
received a CHOP type protocol, 5 dogs (16%) had a COP type protocol, 3 (10%) had a lomustine-251 
based protocol ( lomustine / vincristine / cyclophosphamide; lomustine / prednisolone or lomustine / 252 
prednisolone/ L-asparaginase respectively), 1 dog (2.5%) had doxorubicin single agent and 253 
prednisolone, 1 dog (2.5%) had chlorambucil and prednisolone , and 2 dogs (5%) received only 254 
prednisolone. The response rate to chemotherapy for the 22 dogs that had gross disease at the start of 255 
chemotherapy (only one of the dogs that had surgery had gross residual disease at the start of 256 
chemotherapy) was available in the records of 19 dogs (86%). The overall response rate was 100% 257 
with 18 dogs (95%) having a complete response and 1 dog (5%) a partial response.  258 
The estimated PFS was 1318 days, since 71% of dogs were censored the confidence interval (CI) is 259 
not available. Nine patients had a relapse during the follow up period and reinduction with a 260 
chemotherapy protocol was attempted in 8 of them (six dogs received one additional protocol, one 261 
dog received 2 and one received 5 additional protocols). Chemotherapy protocols used for reinduction 262 
comprised: lomustine/prednisolone with or without L-asparaginase, CHOP, COP, 263 
vincristine/chlorambucil, doxorubicin single agent or vincristine single agent. Two dogs were 264 
euthanized the same day that the chemotherapy was resumed. Response was available for 5 out of the 265 
6 remaining dogs and all had a complete response. The median remission duration for these 5 dogs, 266 
after the first reinduction protocol was initiated, was 411 days (range 298-938). 267 
Outcome: At the end of the study period, 14 dogs were still alive, 5 dogs were lost to follow up, 7 268 
dogs died of lymphoma, and 5 dogs died of unrelated causes (1 intramuscular hemangiosarcoma, 1 269 
suspected osteosarcoma, 1 chronic kidney disease, 2 unknown cause). Only one dog underwent 270 
necropsy and disseminated lymphoma was found to be the cause of his death. The median follow-up 271 
time was 684 days (range 3-4678 days). The estimated disease-related MST where only dogs that died 272 
from lymphoma were considered as events was 1845 days (Figure 2). Since 77.5% of dogs were 273 
censored, the CI was not available. The estimated overall MST, where dogs that died from any causes 274 
were considered as events, was 1548 days (95% CI: 886- 2210). MST calculated only for those 7 275 
patients that died of lymphoma was 643 days (range 399-1845 days) and for the 5 patients dying of 276 
unrelated causes was 789 days (range 465-4678 days). The 1, 2, and 4 year overall survival rates for 277 
all dogs in this study were 100, 50, and 25 %, respectively.  278 
Prognostic factors:  279 
There was no statistically significant association between gender, number of presenting clinical signs 280 
(one versus multiple), type of clinical signs (systemic versus local), location of the disease (solitary vs 281 
multiple/diffuse), involvement of organs other than intestines, immunophenotype (B vs others), grade 282 
(high vs others), treatment (chemotherapy alone versus chemotherapy plus a local treatment) (Figure 283 
3), chemotherapy treatment (CHOP/doxorubicin-based protocol versus others or CHOP vs others) and 284 
either PFS or disease-related MST. The disease-related MST for dogs receiving chemotherapy alone 285 
was 1845 days (95 % CI: 855-2835) versus a median that could not be reached for dogs receiving 286 
chemotherapy plus a local treatment and the difference between these medians was not statistically 287 
significant (p-value 0.584) (Figure 3).  When substage was analysed it was not a statistically 288 
significant risk factor for disease-related MST (p-value = 0.345) but substage b was found to have a 289 
significantly positive impact on PFS (p-value = 0.001), with a PFS that was not reached for dogs 290 
categorized as substage b (95% CI: 0-2331.5) versus a PFS of 271 days for dogs without clinical signs 291 
at diagnosis. The presence of haematochezia at diagnosis was not a statistically significant risk factor 292 
for disease-related MST (p-value = 0.147) but was found to have a significantly positive impact on 293 
PFS (p-value = 0.02), with a PFS of 1141 days for dogs without haematochezia (95% CI: 0-2331.5) 294 
versus a PFS that was not reached for dogs with haematochezia at presentation. Dogs younger than 7 295 
years had longer PFS than dogs older than 7 years (836 days for older dogs, 95% CI: 537-1135 versus 296 
a PFS not reached for younger dogs, p-value = 0.031 and 0.01 respectively) but a similar disease-297 
related MST was present in both groups. 298 
 299 
Discussion 300 
The primary goal of the current study was descriptive, as PCRL has not previously been described in 301 
a large case series in the veterinary literature and just few sparse cases of colorectal lymphoma have 302 
been reported (Table 1). The current study showed that PCRL occurs primarily in middle-aged dogs 303 
with no sex or breed predisposition. Results of this study suggested that PCRL is typically high grade 304 
and B cell immunophenotype with most dogs presenting as substage b. The majority of dogs (23/31; 305 
74.2%) presented with a solitary mass and 13/31 (43.7%) had evidence of involvement of abdominal 306 
extra GI organs (liver or regional lymph nodes). The disease features of dogs with PCRL described in 307 
this study are consistent with cases previously reported.3-5,8,10,15  308 
Results of the present study suggest that dogs with PCRL treated with chemotherapy, with or without 309 
additional local therapy, had a very good prognosis as demonstrated by a high response rate, long 310 
PFS, and long MST. This is in agreement with previous published results 3-5,8,10,15, and in contrast to 311 
the reported low response rate (56%) 4 and short survival time (13-77 days) for dogs with diffuse GI 312 
tract lymphoma of other locations.4,5 The CI could not be calculated for disease-related MST, despite 313 
a median follow-up time of almost 2 years, as 14 (45%) of the dogs in this study were still alive at the 314 
time of writing. Therefore it is possible that the PFS and survival time for dogs with PCRL might be 315 
even longer than has been estimated in our study. For a more accurate determination of disease-316 
related MST, the population in this study would require follow up beyond 2 years. The possibility of 317 
additional deaths unrelated to lymphoma for dogs currently alive and in complete remission besides 318 
the 5 already recorded, could continue adding censored dogs to the statistical analysis which will 319 
make it difficult to reach a defined value for PFS and disease-related MST. We considered that the 320 
improved prognosis of dogs with PCRL found in this study, particularly in comparison to previously 321 
published outcomes of dogs with AL lymphoma, warranted communication to the veterinary 322 
community despite availability only of estimated statistical parameters via the Kaplan Meier method. 323 
A subsequent goal of our study was to evaluate outcome with different treatment modalities for dogs 324 
with PCRL. No statistical difference was found between PFS or survival of dogs receiving 325 
chemotherapy only versus chemotherapy plus local treatment with surgery or radiation. Patients that 326 
received chemotherapy only had a PFS of 1318 days and a disease-related MST of 1845 days, and the 327 
PFS and disease-related MST were not reached for patients that had chemotherapy combined with 328 
local treatment, however, this difference in outcome was not statistically significant. This finding 329 
shows that chemotherapy alone was effective to treat a localized presentation of lymphoma and 330 
surgery or radiation therapy, which carry some morbidity, might delay start of medical anticancer 331 
treatment, and increase total cost of therapy, are not necessarily required to achieve a good outcome.  332 
In this study surgery was performed mainly in cases with presumed solitary large intestine masses 333 
primarily to achieve a diagnosis and we lack information documenting if alternative diagnostic 334 
procedures were previously attempted unrewardingly or why surgery was elected by referring vets as 335 
a diagnostic tool above other diagnostic modalities. It is possible that the differential diagnosis of 336 
PCRL and its implications in the therapeutic approach were not considered due to its rarity in 337 
comparison to other types of colorectal neoplasia for which surgery is routinely recommended. The 338 
findings in this study support consideration of PCRL as a differential for solitary colorectal masses 339 
and when possible the use of low invasive diagnostic techniques such as cytology or incisional biopsy 340 
prior to treatment planning. Due to the retrospective nature of the study, treatment groups were not 341 
randomised and there is a possibility that surgery had been selected more often for dogs with more 342 
advanced diseases and that multimodality treatment would be more beneficial than a single treatment 343 
for advanced disease. On the contrary surgery may also have been elected more often for dogs with 344 
isolated disease, and it might have made a difference in the outcome of PCRL patients, as this has 345 
been described for solitary lesions of lymphoma in other locations.16-18  346 
In this study there was no difference in PFS or survival time based on the type of chemotherapy 347 
protocol used to treat dogs with PCRL. We have to be very cautious in the interpretation of our data 348 
considering that, due to the small number of dogs in the present study, only two chemotherapy groups 349 
could be defined (doxorubicin-based protocol vs others). Still, it is important to consider that these 350 
results describe that less intense chemotherapy protocols, often chosen when facing client economic 351 
or time constraints or when clients seek therapies with potentially lower prevalence of adverse effects, 352 
seem to achieve similar PFS and survival times than with CHOP type protocols. This finding 353 
correlates with a previous studies where an overall survival time of approximately 4.5 years was 354 
reached in 9 dogs with rectal lymphoma receiving either a low dose COP protocol or a truncated (6 355 
weeks) CHOP protocol10. 356 
Age greater than 7 years was associated with a significantly decreased prognosis as compared to dogs 357 
younger than 7 years. Since most dogs had long PFS, it is possible that older patients were more likely 358 
to succumb to concurrent or subsequent morbidities than younger dogs. Decreased owner motivation 359 
to re-start treatment at relapse in older dogs is also a possible reason that these dogs had a shorter 360 
disease-related MST as compared to younger dogs, but this would not explain the shorter PFS 361 
experienced by dogs older than 7 years.  362 
Canine lymphoma patients with systemic signs or clinical signs associated to their presentation with a 363 
systemic impact (substage b) are known to have a worse prognosis.1,19-21 Dogs with AL are often 364 
substage b at diagnosis mainly due to clinical signs associated to local disease and it is possible that 365 
they often are less responsive to therapy due to clinical signs being surrogate markers of more 366 
advanced disease.5,14 GI signs, particularly upper GI signs such as anorexia and vomiting, are often 367 
perceived as poor quality of life by owners, leading to an early decision of euthanasia during the 368 
course of treatment. In the present study, although most dogs presented with clinical signs associated 369 
to PCRL, their symptoms did not appear as severe in nature as GI signs of dogs with diffuse small 370 
intestinal or gastric lymphoma. We decided to consider haematochezia, tenesmus, and diarrhoea as 371 
markers of systemic illness due to the possible associated systemic discomfort and pain and potential 372 
impact in quality of life. Being this a retrospective study with limited recorded information about 373 
severity of clinical signs and impact on the dogs’ general status, grading of GI signs at presentation 374 
according to the VCOG criteria22 was not possible and precluded a comparison with previous studies 375 
about canine AL. Interestingly in this study there was no difference in outcome for dogs with systemic 376 
versus local signs and substage did not have an impact in survival time. Although PFS of dogs 377 
without clinical signs was shorter than for dogs with substage b (271 days versus not reached), these 378 
results could have been biased due to the small number of dogs in the substage a group or potential 379 
missing data regarding patient’s clinical signs. More information is needed to ascertain how best to 380 
apply the current canine lymphoma staging system to extranodal forms like PCRL and to identify its 381 
value in determining prognosis. 382 
The presence of haematochezia at diagnosis was found to have a positive impact on the PFS 383 
compared to other signs. For the 20 dogs presenting with haematochezia, the PFS was not reached, 384 
compared with 1141 days for 9 dogs without haematochezia but with other clinical signs. It is not 385 
clear why haematochezia would have a positive impact on the prognosis. Perhaps this was more 386 
alarming for owners than diarrhoea and its observation might have led to earlier diagnosis and 387 
treatment. On the other hand, we can also assume that other signs reported (diarrhoea, rectal prolapse, 388 
tenesmus) might be associated with more advanced disease and decreased outcome, however 13/20 389 
cases with haematochezia also had additional clinical signs. This result could also be secondary to a 390 
statistical bias; a larger population would help to determine if the presence or absence of 391 
haematochezia truly has an impact on prognosis.  392 
In previous studies on canine AL, the immunophenotype was most commonly of T-cell origin.5,6,8,23-25 393 
We report here that colorectal lymphoma is most commonly of B-cell origin, raising a clear 394 
distinction from other GI locations. The B-cell phenotype in canine high-grade lymphoma generally is 395 
associated with a better response to conventional chemotherapy protocols, compared with the T 396 
immunophenotype.19,26 In the current study, 77% of the dogs were of immunophenotype B, there were 397 
only 2 cases of known non-B immunophenotype with outcomes comparable to the ones with 398 
immunophenotype B  (survival times 491 and 1273 days) and 5 cases with unknown 399 
immunophenotype (Table 2). We did not find any impact of immunophenotype on outcome but the 400 
low number of dogs with non-B phenotype included in the study clearly precludes knowing the real 401 
impact of this factor in PCRL.  402 
The most common grade for lymphoma found in this study was high (58% of the dogs) and was not a 403 
significant prognostic factor in our population. The grading was performed based on the National 404 
Cancer Institute working formulation with separation of the patients into 3 categories: low, 405 
intermediate, and high grade.11-13 Recent studies advise for classification of canine lymphomas 406 
according to the WHO classification 7,28 in order to standardise future study populations as this may 407 
have a prognostic significance.27 This would be extremely interesting for canine PCRL in order to  408 
further characterize and describe this anatomical presentation. However, in this retrospective study, 409 
the limited availability of initial tissue samples and absence of immunophenotype for some dogs has 410 
precluded this classification. Other studies that classified their patients according to the working 411 
formulation into low, intermediate, and high grade13 found that grade had prognostic significance.12 In 412 
our study, there were too few dogs in the low or intermediate grade category and perhaps this could 413 
have an impact on the statistical significance. Interestingly, despite most dogs having high grade B 414 
cell lymphoma, their disease-related MST was much longer (1845 days) than that of dogs affected by 415 
the multicentric form of same grade and immunopenotype (MST reported in literature of 162-308 416 
days12), reinforcing the fact that anatomic site seems to be a better predictor of outcome than 417 
previously published prognostic factors.  418 
Information available for staging of dogs included in this study was limited due to its retrospective 419 
nature and staging performed was quite heterogeneous due to the high number of participating 420 
institutions. This was unfortunately unavoidable when trying to compile a large case series of PCRL 421 
due to its low prevalence. Staging was not complete for all dogs and different imaging modalities 422 
were used. In addition, even imaging techniques used routinely for staging in veterinary oncology 423 
such as abdominal ultrasound or computed tomography have limitations for detection of lymphoma. 424 
Also aspirates of liver and spleen were not routinely performed despite knowledge that neoplastic 425 
infiltration is possible even with a normal imaging appearance29. In this study, twelve dogs had 426 
evidence of regional lymphadenopathy and one hepatic involvement without impact on PFS or 427 
survival time. It is very possible that a higher number of dogs had a higher stage of disease than 428 
recorded leading to erroneous staging classification of cases (stage migration)30 and this could explain 429 
the lack of statistical difference. On the other hand, given the overall long PFS and survival times for 430 
all patients, it could also be thought that possibly under-staged dogs had a good outcome. Based on 431 
this study’s data it seems that presence of complete staging would not have provided any further 432 
prognostic information for dogs with PCRL. However, as there is not established standard treatment 433 
for PCRL, it would be advisable that complete staging would be performed to outweigh potential 434 
advantages versus morbidity/cost if considering local therapy prior to chemotherapy or as solely 435 
therapy in PCRL. 436 
Human primary AL are classified as confined to the GI tract, with no other evidence of systemic 437 
involvement (see figure 1). They are most often of B cell origin8, which is comparable to our study 438 
findings, but opposite to the immunophenotype of canine AL6. PCRL is a rare disease in human 439 
medicine31 with controversy about what the standard of care should be for its treatment.31 Long 440 
survivals have been described with 83% of the patients alive and free of disease at 10 years after a 441 
combination of surgery and chemotherapy.32 but shorter prognosis with a 5 year survival rate of 47% 442 
has also been reported.33 In people, the two most frequent histologic subtypes of PCRL are mucosa-443 
associated lymphoid tissue (MALT) lymphoma and diffuse large B cell lymphoma with both PCRL 444 
types carrying very different prognosis. The MALT form, of low grade and B-cell origin, can be cured 445 
after surgical resection and/or a short course of chemotherapy. The prognosis is more guarded for the 446 
diffuse large B cell lymphoma which carries a high relapse rate (33-75%).34 Interestingly, although 447 
most cases of canine PRCL in our population were high grade and B-cell origin the biologic 448 
behaviour seems to differ from the high grade form of human PRCL.   449 
The limitations of this study are inherent to it retrospective design and include small sample size, 450 
variable staging and treatment regimens, and lack of standardized follow-up. The small population 451 
due to the rarity of the disease limited the statistical power of our analyses and prognostic factors 452 
associated with PFS and disease-related MST may not have been identified due to the variations in 453 
staging and treatment protocols. Of the factors analysed, few were found to be prognostic indicators in 454 
exploratory univariate analysis. Unfortunately, multivariate analysis could not be carried out as too 455 
many dogs were censored mostly due to long survival, loss of follow-up, or death from unrelated 456 
cause. Evaluation of a larger sample size, prospectively, over a longer period of time including 457 
standardized comprehensive staging and standardized therapy would be ideal and may permit 458 
determination of additional characteristics and identify risk factors for PCRL. This would be 459 
challenging, requiring even further collaboration than the one required for this study (with 18 460 
institutions collaborating in 4 countries) due to the low prevalence of this presentation of canine 461 
lymphoma. It needs to be reinforced that larger number of dogs and longer follow-up may still not 462 
reach statistical significance if most patients do not demonstrate events linked to their lymphoma 463 
(relapse or death) as they would remain censored from the whole population should they remain in 464 
remission or die from other causes.  465 
In conclusion, results of the present study describe canine PCRL as a rare disease often of high grade 466 
and B-cell immunophenotype that when treated with chemotherapy results in prolonged PFS and 467 
survival times regardless of chemotherapy protocol type or addition of local treatment modalities. 468 
Results of this study suggest that PCRL has a greatly improved outcome compared to previously 469 
published outcomes of dogs with AL. Therefore, attempts to differentiate dogs with PCRL from dogs 470 
with diffuse GI lymphoma should be pursued in order to better guide owners regarding treatment and 471 
associated prognosis. Veterinarian awareness of this specific presentation of canine lymphoma will 472 
likely have an important impact on the treatment decision process for owners of dogs with PCRL.  473 
 474 
Footnotes 475 
a. (SPSS version 19.0 for Windows, SPSS Inc, Chicago, Ill).  476 
 477 
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Chemotherapy: COAP protocol 
 
>54 months  3 
7 Rectum  histology NA 
Surgery 5 weeks, 1 dog 
had no relapse 
after 8 months, 
1 relapsed but 
was still alive 





5 histology  
1 cytology  
NA 
4 chemotherapy only  (type NA) 




1  Colon histology T VELCAP-SC protocol NA 4 
1  Rectum  histology NA COP protocol > 356 days 8 
11 Rectum  histology 10 B 
6 surgery + chemotherapy 
(CHOP/COP) 
1 surgery alone 
3 chemotherapy (CHOP/COP or 
prednisolone) 
1 no treatment 






Table 2: Location, extension, histologic characteristics, and treatment data of dogs with colorectal 609 
lymphoma.  610 
Data Number of cases 
Aspect 23 solitary masses 
  5 multiple masses 
  3 diffuse disease 
Location 18 rectal disease 
7 colonic disease 
6 colorectal disease 
Staging 12 lymph node involvement 
  1 liver involvement 
Substage 29 substage b 
2 unknown 
Immunophenotype 24 B   
  1 T   
 1 non B non T 
5 non available 
Grade 18 high    
  9 intermediate 
  2 low 
2 non available   
Treatment  1 surgery   
  17 chemotherapy 
  9 chemotherapy + surgery 
4 chemotherapy + radiotherapy  
Chemotherapy protocol 18 CHOP   
  5 COP   
  1 doxorubicin 
  3 lomustine 
  1 chlorambucil + prednisolone 
  2 prednisolone 
 611 
  612 







Figure 2: Kaplan Meier of the estimated survival time with the event being dogs that died from 620 
lymphoma. The estimated MST was 1845 days (confidence interval not available). 621 
 622 
  623 
Dawson’s criteria: 
- No generalized, superficial, or mediastinal lymphadenopathy 
- No leukemic or lymphomatous abnormalities in the peripheral blood 
- Lesion confined to the bowel, with only regional lymphadenopathy at the time of 
laparotomy 
- No involvement of the spleen or the liver at the time of diagnosis 
 
Figure 3: Kaplan Meier of the estimated survival time for dogs receiving chemotherapy versus dogs 624 
receiving chemotherapy plus a local treatment. The addition of a local treatment to chemotherapy did 625 
not impact the overall prognosis (p-value = 0.564). 626 
 627 
